RGLSRegulus TherapeuticsRGLS info
$1.59info2.58%24h
Global rank25518
Market cap$32.15M
Change 7d1.27%
YTD Performance21.37%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Regulus Therapeutics (RGLS) Stock Overview

    Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

    RGLS Stock Information

    Symbol
    RGLS
    Address
    4224 Campus Point CourtSan Diego, CA 92121United States
    Founded
    -
    Trading hours
    -
    Website
    https://www.regulusrx.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    858 202 6300

    Regulus Therapeutics (RGLS) Price Chart

    -
    Value:-

    Regulus Therapeutics Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $1.59
    N/A
    Market Cap
    $32.15M
    N/A
    Shares Outstanding
    20.22M
    N/A
    Employees
    29.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org